Literature DB >> 28561372

MxA is a positive regulator of type I IFN signaling in HCV infection.

Xuezhen Shi1, Baihai Jiao1, Yanzhao Chen1, Shilin Li1, Limin Chen1,2.   

Abstract

Type I interferons (IFNs) are a family of primordial cytokines that respond to various pathogen infections including Hepatitis C virus (HCV). Type I IFNs signal through Jak/STAT pathway leading to the production of a few hundred interferon stimulated genes (ISGs). The aim of this study was to explore the role of one of these ISGs, MxA in HCV infection and type I IFN production. Plasmid encoding MxA was cloned into PcDNA3.1-3×tag vector and MxA expression was confirmed both at mRNA (RT-PCR) and protein (Western blot, WB) levels. IFNα and IFNβ productions were quantified by RT-PCR from cell lysate and by ELISA kit from culture medium following MxA over-expression in Huh7.5.1 cells. The activation status of Jak/STAT signaling pathway was examined at three levels: p-STAT1 (WB), interferon sensitive response element (ISRE) activity (dual luciferase reporter gene assay), and levels of ISG expression (RT-qPCR). J6/JFH1 HCV culture system was used to study the role of MxA in HCV replication. Our findings indicated that MxA over-expression inhibited HCV replication and potentiated the IFNα-mediated anti-HCV activity; MxA stimulated the production of IFNα, IFNβ, and enhanced IFNα-induced activation of Jak-STAT signaling pathway. We concluded that MxA is a positive regulator of type I IFN signaling in HCV infection.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  hepatitis C virus (HCV); janus kinase-signal transducers and activators of transcription (Jak/STAT) pathway; myxovirus resistance-A (MxA/Mx1); positive regulator; type I interferons (IFNs)

Mesh:

Substances:

Year:  2017        PMID: 28561372     DOI: 10.1002/jmv.24867

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.

Authors:  Yanan Zhao; Xuezhi Cao; Mingzhe Guo; Xuesong Wang; Tao Yu; Liqing Ye; Lin Han; Lei Hei; Wanyin Tao; Yimin Tong; Yongfen Xu; Jin Zhong
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

Review 2.  Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection.

Authors:  Ana Maria Ortega-Prieto; Marcus Dorner
Journal:  Vaccines (Basel)       Date:  2017-09-01

Review 3.  Long Non-coding RNAs in Hepatitis C Virus-Infected Cells.

Authors:  Marina Barriocanal; Puri Fortes
Journal:  Front Microbiol       Date:  2017-09-28       Impact factor: 5.640

4.  Interferon-α-induced cytoplasmic MxA structures in hepatoma Huh7 and primary endothelial cells.

Authors:  Deodate Davis; Huijuan Yuan; Yang-Ming Yang; Feng-Xia Liang; Pravin B Sehgal
Journal:  Contemp Oncol (Pozn)       Date:  2018-06-01

Review 5.  Decoding type I and III interferon signalling during viral infection.

Authors:  Emily V Mesev; Robert A LeDesma; Alexander Ploss
Journal:  Nat Microbiol       Date:  2019-04-01       Impact factor: 17.745

6.  2', 5'-Oligoadenylate Synthetase 2 (OAS2) Inhibits Zika Virus Replication through Activation of Type Ι IFN Signaling Pathway.

Authors:  Xinzhong Liao; He Xie; Shilin Li; Haiyan Ye; Shuang Li; Kai Ren; Yujia Li; Min Xu; Wenyu Lin; Xiaoqiong Duan; Chunhui Yang; Limin Chen
Journal:  Viruses       Date:  2020-04-08       Impact factor: 5.048

7.  MxB is an interferon-induced restriction factor of human herpesviruses.

Authors:  Michel Crameri; Michael Bauer; Nicole Caduff; Raphael Walker; Fiona Steiner; Francesca D Franzoso; Cornelia Gujer; Karin Boucke; Talissa Kucera; Andrea Zbinden; Christian Münz; Cornel Fraefel; Urs F Greber; Jovan Pavlovic
Journal:  Nat Commun       Date:  2018-05-17       Impact factor: 14.919

8.  HIV-1 Promotes the Degradation of Components of the Type 1 IFN JAK/STAT Pathway and Blocks Anti-viral ISG Induction.

Authors:  Siobhan Gargan; Suaad Ahmed; Rebecca Mahony; Ciaran Bannan; Silvia Napoletano; Cliona O'Farrelly; Persephone Borrow; Colm Bergin; Nigel J Stevenson
Journal:  EBioMedicine       Date:  2018-03-09       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.